nodes	percent_of_prediction	percent_of_DWPC	metapath
Ticagrelor—ABCB1—Mitoxantrone—lymphatic system cancer	0.132	0.206	CbGbCtD
Ticagrelor—CYP3A4—Cytarabine—lymphatic system cancer	0.115	0.18	CbGbCtD
Ticagrelor—CYP3A4—Teniposide—lymphatic system cancer	0.113	0.177	CbGbCtD
Ticagrelor—ABCB1—Vincristine—lymphatic system cancer	0.0908	0.142	CbGbCtD
Ticagrelor—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0791	0.124	CbGbCtD
Ticagrelor—ABCB1—Methotrexate—lymphatic system cancer	0.055	0.086	CbGbCtD
Ticagrelor—CYP3A4—Vincristine—lymphatic system cancer	0.0544	0.0851	CbGbCtD
Ticagrelor—Cardiac tamponade—Methotrexate—lymphatic system cancer	0.00944	0.0262	CcSEcCtD
Ticagrelor—Transient ischaemic attack—Fludarabine—lymphatic system cancer	0.00854	0.0237	CcSEcCtD
Ticagrelor—Nephropathy toxic—Teniposide—lymphatic system cancer	0.00854	0.0237	CcSEcCtD
Ticagrelor—Petechiae—Mechlorethamine—lymphatic system cancer	0.00809	0.0224	CcSEcCtD
Ticagrelor—Oliguria—Mechlorethamine—lymphatic system cancer	0.00722	0.02	CcSEcCtD
Ticagrelor—Gastrointestinal ulcer haemorrhage—Methotrexate—lymphatic system cancer	0.00667	0.0185	CcSEcCtD
Ticagrelor—Haemorrhage intracranial—Mitoxantrone—lymphatic system cancer	0.00625	0.0173	CcSEcCtD
Ticagrelor—Haemoptysis—Fludarabine—lymphatic system cancer	0.00583	0.0161	CcSEcCtD
Ticagrelor—Nephropathy toxic—Bleomycin—lymphatic system cancer	0.0055	0.0153	CcSEcCtD
Ticagrelor—Cerebral haemorrhage—Carmustine—lymphatic system cancer	0.00498	0.0138	CcSEcCtD
Ticagrelor—Nephropathy toxic—Carmustine—lymphatic system cancer	0.0048	0.0133	CcSEcCtD
Ticagrelor—Cerebral haemorrhage—Vincristine—lymphatic system cancer	0.00476	0.0132	CcSEcCtD
Ticagrelor—Hyperuricaemia—Fludarabine—lymphatic system cancer	0.00465	0.0129	CcSEcCtD
Ticagrelor—Nephropathy toxic—Mitoxantrone—lymphatic system cancer	0.00447	0.0124	CcSEcCtD
Ticagrelor—Blood uric acid increased—Fludarabine—lymphatic system cancer	0.00439	0.0122	CcSEcCtD
Ticagrelor—Serum creatinine increased—Mitoxantrone—lymphatic system cancer	0.00417	0.0116	CcSEcCtD
Ticagrelor—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.00345	0.00957	CcSEcCtD
Ticagrelor—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.00336	0.00931	CcSEcCtD
Ticagrelor—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.00334	0.00926	CcSEcCtD
Ticagrelor—Cardiac failure—Fludarabine—lymphatic system cancer	0.00321	0.00889	CcSEcCtD
Ticagrelor—Gastrointestinal haemorrhage—Fludarabine—lymphatic system cancer	0.00313	0.00868	CcSEcCtD
Ticagrelor—Petechiae—Mitoxantrone—lymphatic system cancer	0.00312	0.00864	CcSEcCtD
Ticagrelor—Contusion—Mitoxantrone—lymphatic system cancer	0.00294	0.00815	CcSEcCtD
Ticagrelor—Hyperuricaemia—Vincristine—lymphatic system cancer	0.00284	0.00787	CcSEcCtD
Ticagrelor—Hyperuricaemia—Mitoxantrone—lymphatic system cancer	0.00277	0.00767	CcSEcCtD
Ticagrelor—Blood uric acid increased—Vincristine—lymphatic system cancer	0.00268	0.00744	CcSEcCtD
Ticagrelor—Vertigo—Mechlorethamine—lymphatic system cancer	0.00261	0.00724	CcSEcCtD
Ticagrelor—Blood uric acid increased—Mitoxantrone—lymphatic system cancer	0.00261	0.00724	CcSEcCtD
Ticagrelor—Haemoglobin—Teniposide—lymphatic system cancer	0.00248	0.00686	CcSEcCtD
Ticagrelor—Gynaecomastia—Carmustine—lymphatic system cancer	0.00247	0.00684	CcSEcCtD
Ticagrelor—Haemorrhage—Teniposide—lymphatic system cancer	0.00246	0.00683	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00246	0.00682	CcSEcCtD
Ticagrelor—Ecchymosis—Mitoxantrone—lymphatic system cancer	0.00232	0.00643	CcSEcCtD
Ticagrelor—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00231	0.00639	CcSEcCtD
Ticagrelor—Haematuria—Fludarabine—lymphatic system cancer	0.0023	0.00637	CcSEcCtD
Ticagrelor—Epistaxis—Fludarabine—lymphatic system cancer	0.00227	0.00631	CcSEcCtD
Ticagrelor—Haemoglobin—Fludarabine—lymphatic system cancer	0.00218	0.00603	CcSEcCtD
Ticagrelor—Haemorrhage—Fludarabine—lymphatic system cancer	0.00217	0.006	CcSEcCtD
Ticagrelor—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00205	0.00569	CcSEcCtD
Ticagrelor—Renal failure acute—Mitoxantrone—lymphatic system cancer	0.00202	0.00559	CcSEcCtD
Ticagrelor—Gastrointestinal haemorrhage—Carmustine—lymphatic system cancer	0.002	0.00555	CcSEcCtD
Ticagrelor—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00191	0.00529	CcSEcCtD
Ticagrelor—Malnutrition—Fludarabine—lymphatic system cancer	0.00188	0.00522	CcSEcCtD
Ticagrelor—Gastrointestinal haemorrhage—Mitoxantrone—lymphatic system cancer	0.00186	0.00516	CcSEcCtD
Ticagrelor—Hypertension—Teniposide—lymphatic system cancer	0.00185	0.00513	CcSEcCtD
Ticagrelor—Haematemesis—Methotrexate—lymphatic system cancer	0.00184	0.0051	CcSEcCtD
Ticagrelor—Chest pain—Teniposide—lymphatic system cancer	0.00183	0.00506	CcSEcCtD
Ticagrelor—Lung disorder—Methotrexate—lymphatic system cancer	0.00181	0.00501	CcSEcCtD
Ticagrelor—Confusional state—Teniposide—lymphatic system cancer	0.00176	0.00489	CcSEcCtD
Ticagrelor—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00175	0.00485	CcSEcCtD
Ticagrelor—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00174	0.00484	CcSEcCtD
Ticagrelor—Haematuria—Bleomycin—lymphatic system cancer	0.00169	0.00467	CcSEcCtD
Ticagrelor—Pruritus—Mechlorethamine—lymphatic system cancer	0.00168	0.00466	CcSEcCtD
Ticagrelor—Cough—Fludarabine—lymphatic system cancer	0.00164	0.00456	CcSEcCtD
Ticagrelor—Hypotension—Teniposide—lymphatic system cancer	0.00164	0.00453	CcSEcCtD
Ticagrelor—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00162	0.0045	CcSEcCtD
Ticagrelor—Haemoglobin—Bleomycin—lymphatic system cancer	0.0016	0.00442	CcSEcCtD
Ticagrelor—Haemorrhage—Bleomycin—lymphatic system cancer	0.00159	0.0044	CcSEcCtD
Ticagrelor—Dyspnoea—Teniposide—lymphatic system cancer	0.00156	0.00433	CcSEcCtD
Ticagrelor—Petechiae—Methotrexate—lymphatic system cancer	0.00155	0.00431	CcSEcCtD
Ticagrelor—Confusional state—Fludarabine—lymphatic system cancer	0.00155	0.0043	CcSEcCtD
Ticagrelor—Vomiting—Mechlorethamine—lymphatic system cancer	0.00151	0.00418	CcSEcCtD
Ticagrelor—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00151	0.00418	CcSEcCtD
Ticagrelor—Rash—Mechlorethamine—lymphatic system cancer	0.0015	0.00415	CcSEcCtD
Ticagrelor—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0015	0.00415	CcSEcCtD
Ticagrelor—Feeling abnormal—Teniposide—lymphatic system cancer	0.00144	0.004	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00143	0.00397	CcSEcCtD
Ticagrelor—Bone disorder—Methotrexate—lymphatic system cancer	0.00142	0.00392	CcSEcCtD
Ticagrelor—Nausea—Mechlorethamine—lymphatic system cancer	0.00141	0.00391	CcSEcCtD
Ticagrelor—Haemoglobin—Carmustine—lymphatic system cancer	0.00139	0.00386	CcSEcCtD
Ticagrelor—Oliguria—Methotrexate—lymphatic system cancer	0.00139	0.00384	CcSEcCtD
Ticagrelor—Haemorrhage—Carmustine—lymphatic system cancer	0.00139	0.00384	CcSEcCtD
Ticagrelor—Abdominal pain—Teniposide—lymphatic system cancer	0.00138	0.00384	CcSEcCtD
Ticagrelor—Body temperature increased—Teniposide—lymphatic system cancer	0.00138	0.00384	CcSEcCtD
Ticagrelor—Paraesthesia—Fludarabine—lymphatic system cancer	0.00138	0.00383	CcSEcCtD
Ticagrelor—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.00138	0.00382	CcSEcCtD
Ticagrelor—Dyspnoea—Fludarabine—lymphatic system cancer	0.00137	0.0038	CcSEcCtD
Ticagrelor—Haematuria—Mitoxantrone—lymphatic system cancer	0.00137	0.00379	CcSEcCtD
Ticagrelor—Oedema peripheral—Carmustine—lymphatic system cancer	0.00137	0.00378	CcSEcCtD
Ticagrelor—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00136	0.00377	CcSEcCtD
Ticagrelor—Dyspepsia—Fludarabine—lymphatic system cancer	0.00135	0.00375	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00133	0.00368	CcSEcCtD
Ticagrelor—Fatigue—Fludarabine—lymphatic system cancer	0.00133	0.00368	CcSEcCtD
Ticagrelor—Constipation—Fludarabine—lymphatic system cancer	0.00132	0.00365	CcSEcCtD
Ticagrelor—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00131	0.00364	CcSEcCtD
Ticagrelor—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00131	0.00362	CcSEcCtD
Ticagrelor—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.0013	0.00361	CcSEcCtD
Ticagrelor—Connective tissue disorder—Vincristine—lymphatic system cancer	0.0013	0.0036	CcSEcCtD
Ticagrelor—Urethral disorder—Vincristine—lymphatic system cancer	0.0013	0.00359	CcSEcCtD
Ticagrelor—Eye disorder—Carmustine—lymphatic system cancer	0.0013	0.00359	CcSEcCtD
Ticagrelor—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00129	0.00359	CcSEcCtD
Ticagrelor—Hypersensitivity—Teniposide—lymphatic system cancer	0.00129	0.00357	CcSEcCtD
Ticagrelor—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00129	0.00357	CcSEcCtD
Ticagrelor—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00127	0.00351	CcSEcCtD
Ticagrelor—Asthenia—Teniposide—lymphatic system cancer	0.00126	0.00348	CcSEcCtD
Ticagrelor—Melaena—Methotrexate—lymphatic system cancer	0.00125	0.00346	CcSEcCtD
Ticagrelor—Pruritus—Teniposide—lymphatic system cancer	0.00124	0.00343	CcSEcCtD
Ticagrelor—Cardiac disorder—Vincristine—lymphatic system cancer	0.00123	0.0034	CcSEcCtD
Ticagrelor—Body temperature increased—Fludarabine—lymphatic system cancer	0.00122	0.00337	CcSEcCtD
Ticagrelor—Mental disorder—Carmustine—lymphatic system cancer	0.00121	0.00336	CcSEcCtD
Ticagrelor—Malnutrition—Carmustine—lymphatic system cancer	0.00121	0.00334	CcSEcCtD
Ticagrelor—Cough—Bleomycin—lymphatic system cancer	0.00121	0.00334	CcSEcCtD
Ticagrelor—Angiopathy—Vincristine—lymphatic system cancer	0.0012	0.00333	CcSEcCtD
Ticagrelor—Diarrhoea—Teniposide—lymphatic system cancer	0.0012	0.00332	CcSEcCtD
Ticagrelor—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00119	0.0033	CcSEcCtD
Ticagrelor—Chest pain—Bleomycin—lymphatic system cancer	0.00118	0.00326	CcSEcCtD
Ticagrelor—Back pain—Carmustine—lymphatic system cancer	0.00117	0.00323	CcSEcCtD
Ticagrelor—Mental disorder—Vincristine—lymphatic system cancer	0.00116	0.00321	CcSEcCtD
Ticagrelor—Ecchymosis—Methotrexate—lymphatic system cancer	0.00116	0.0032	CcSEcCtD
Ticagrelor—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00114	0.00317	CcSEcCtD
Ticagrelor—Confusional state—Bleomycin—lymphatic system cancer	0.00114	0.00315	CcSEcCtD
Ticagrelor—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00113	0.00314	CcSEcCtD
Ticagrelor—Back pain—Vincristine—lymphatic system cancer	0.00111	0.00309	CcSEcCtD
Ticagrelor—Vomiting—Teniposide—lymphatic system cancer	0.00111	0.00308	CcSEcCtD
Ticagrelor—Asthenia—Fludarabine—lymphatic system cancer	0.0011	0.00306	CcSEcCtD
Ticagrelor—Rash—Teniposide—lymphatic system cancer	0.0011	0.00306	CcSEcCtD
Ticagrelor—Dermatitis—Teniposide—lymphatic system cancer	0.0011	0.00306	CcSEcCtD
Ticagrelor—Headache—Teniposide—lymphatic system cancer	0.0011	0.00304	CcSEcCtD
Ticagrelor—Pruritus—Fludarabine—lymphatic system cancer	0.00109	0.00302	CcSEcCtD
Ticagrelor—Back pain—Mitoxantrone—lymphatic system cancer	0.00108	0.00301	CcSEcCtD
Ticagrelor—Hypotension—Bleomycin—lymphatic system cancer	0.00105	0.00292	CcSEcCtD
Ticagrelor—Diarrhoea—Fludarabine—lymphatic system cancer	0.00105	0.00292	CcSEcCtD
Ticagrelor—Hypertension—Carmustine—lymphatic system cancer	0.00104	0.00289	CcSEcCtD
Ticagrelor—Nausea—Teniposide—lymphatic system cancer	0.00104	0.00288	CcSEcCtD
Ticagrelor—Vertigo—Vincristine—lymphatic system cancer	0.00103	0.00287	CcSEcCtD
Ticagrelor—Chest pain—Carmustine—lymphatic system cancer	0.00103	0.00285	CcSEcCtD
Ticagrelor—Paraesthesia—Bleomycin—lymphatic system cancer	0.00101	0.00281	CcSEcCtD
Ticagrelor—Dyspnoea—Bleomycin—lymphatic system cancer	0.00101	0.00279	CcSEcCtD
Ticagrelor—Renal failure acute—Methotrexate—lymphatic system cancer	0.001	0.00279	CcSEcCtD
Ticagrelor—Hypertension—Vincristine—lymphatic system cancer	0.000994	0.00276	CcSEcCtD
Ticagrelor—Confusional state—Carmustine—lymphatic system cancer	0.000993	0.00275	CcSEcCtD
Ticagrelor—Cough—Mitoxantrone—lymphatic system cancer	0.000979	0.00271	CcSEcCtD
Ticagrelor—Vomiting—Fludarabine—lymphatic system cancer	0.000978	0.00271	CcSEcCtD
Ticagrelor—Rash—Fludarabine—lymphatic system cancer	0.00097	0.00269	CcSEcCtD
Ticagrelor—Dermatitis—Fludarabine—lymphatic system cancer	0.000969	0.00269	CcSEcCtD
Ticagrelor—Hypertension—Mitoxantrone—lymphatic system cancer	0.000968	0.00268	CcSEcCtD
Ticagrelor—Headache—Fludarabine—lymphatic system cancer	0.000964	0.00267	CcSEcCtD
Ticagrelor—Chest pain—Mitoxantrone—lymphatic system cancer	0.000955	0.00265	CcSEcCtD
Ticagrelor—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000929	0.00258	CcSEcCtD
Ticagrelor—Confusional state—Mitoxantrone—lymphatic system cancer	0.000923	0.00256	CcSEcCtD
Ticagrelor—Nervous system disorder—Vincristine—lymphatic system cancer	0.000922	0.00255	CcSEcCtD
Ticagrelor—Hypotension—Carmustine—lymphatic system cancer	0.00092	0.00255	CcSEcCtD
Ticagrelor—Nausea—Fludarabine—lymphatic system cancer	0.000914	0.00253	CcSEcCtD
Ticagrelor—Shock—Mitoxantrone—lymphatic system cancer	0.0009	0.0025	CcSEcCtD
Ticagrelor—Body temperature increased—Bleomycin—lymphatic system cancer	0.000892	0.00247	CcSEcCtD
Ticagrelor—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000889	0.00246	CcSEcCtD
Ticagrelor—Paraesthesia—Carmustine—lymphatic system cancer	0.000884	0.00245	CcSEcCtD
Ticagrelor—Hypotension—Vincristine—lymphatic system cancer	0.000878	0.00243	CcSEcCtD
Ticagrelor—Dyspnoea—Carmustine—lymphatic system cancer	0.000878	0.00243	CcSEcCtD
Ticagrelor—Hypotension—Mitoxantrone—lymphatic system cancer	0.000855	0.00237	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00085	0.00236	CcSEcCtD
Ticagrelor—Paraesthesia—Vincristine—lymphatic system cancer	0.000844	0.00234	CcSEcCtD
Ticagrelor—Constipation—Carmustine—lymphatic system cancer	0.000842	0.00233	CcSEcCtD
Ticagrelor—Breast disorder—Methotrexate—lymphatic system cancer	0.000838	0.00232	CcSEcCtD
Ticagrelor—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000831	0.0023	CcSEcCtD
Ticagrelor—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000822	0.00228	CcSEcCtD
Ticagrelor—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000816	0.00226	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000811	0.00225	CcSEcCtD
Ticagrelor—Feeling abnormal—Carmustine—lymphatic system cancer	0.000811	0.00225	CcSEcCtD
Ticagrelor—Fatigue—Vincristine—lymphatic system cancer	0.00081	0.00225	CcSEcCtD
Ticagrelor—Asthenia—Bleomycin—lymphatic system cancer	0.000809	0.00224	CcSEcCtD
Ticagrelor—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000806	0.00223	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000805	0.00223	CcSEcCtD
Ticagrelor—Constipation—Vincristine—lymphatic system cancer	0.000804	0.00223	CcSEcCtD
Ticagrelor—Pruritus—Bleomycin—lymphatic system cancer	0.000798	0.00221	CcSEcCtD
Ticagrelor—Fatigue—Mitoxantrone—lymphatic system cancer	0.000789	0.00219	CcSEcCtD
Ticagrelor—Constipation—Mitoxantrone—lymphatic system cancer	0.000783	0.00217	CcSEcCtD
Ticagrelor—Abdominal pain—Carmustine—lymphatic system cancer	0.000778	0.00216	CcSEcCtD
Ticagrelor—Body temperature increased—Carmustine—lymphatic system cancer	0.000778	0.00216	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000769	0.00213	CcSEcCtD
Ticagrelor—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000754	0.00209	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000748	0.00207	CcSEcCtD
Ticagrelor—Body temperature increased—Vincristine—lymphatic system cancer	0.000743	0.00206	CcSEcCtD
Ticagrelor—Abdominal pain—Vincristine—lymphatic system cancer	0.000743	0.00206	CcSEcCtD
Ticagrelor—Hypersensitivity—Carmustine—lymphatic system cancer	0.000725	0.00201	CcSEcCtD
Ticagrelor—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000724	0.00201	CcSEcCtD
Ticagrelor—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000724	0.00201	CcSEcCtD
Ticagrelor—Vomiting—Bleomycin—lymphatic system cancer	0.000717	0.00199	CcSEcCtD
Ticagrelor—Rash—Bleomycin—lymphatic system cancer	0.000711	0.00197	CcSEcCtD
Ticagrelor—Dermatitis—Bleomycin—lymphatic system cancer	0.00071	0.00197	CcSEcCtD
Ticagrelor—Asthenia—Carmustine—lymphatic system cancer	0.000706	0.00196	CcSEcCtD
Ticagrelor—Hypersensitivity—Vincristine—lymphatic system cancer	0.000692	0.00192	CcSEcCtD
Ticagrelor—Haematuria—Methotrexate—lymphatic system cancer	0.000682	0.00189	CcSEcCtD
Ticagrelor—Epistaxis—Methotrexate—lymphatic system cancer	0.000674	0.00187	CcSEcCtD
Ticagrelor—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000674	0.00187	CcSEcCtD
Ticagrelor—Asthenia—Vincristine—lymphatic system cancer	0.000674	0.00187	CcSEcCtD
Ticagrelor—Diarrhoea—Carmustine—lymphatic system cancer	0.000674	0.00187	CcSEcCtD
Ticagrelor—Nausea—Bleomycin—lymphatic system cancer	0.00067	0.00186	CcSEcCtD
Ticagrelor—Asthenia—Mitoxantrone—lymphatic system cancer	0.000657	0.00182	CcSEcCtD
Ticagrelor—Dizziness—Carmustine—lymphatic system cancer	0.000651	0.0018	CcSEcCtD
Ticagrelor—Haemoglobin—Methotrexate—lymphatic system cancer	0.000645	0.00179	CcSEcCtD
Ticagrelor—Diarrhoea—Vincristine—lymphatic system cancer	0.000643	0.00178	CcSEcCtD
Ticagrelor—Haemorrhage—Methotrexate—lymphatic system cancer	0.000642	0.00178	CcSEcCtD
Ticagrelor—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000634	0.00176	CcSEcCtD
Ticagrelor—Urethral disorder—Methotrexate—lymphatic system cancer	0.000629	0.00174	CcSEcCtD
Ticagrelor—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000626	0.00174	CcSEcCtD
Ticagrelor—Vomiting—Carmustine—lymphatic system cancer	0.000626	0.00174	CcSEcCtD
Ticagrelor—Dizziness—Vincristine—lymphatic system cancer	0.000621	0.00172	CcSEcCtD
Ticagrelor—Rash—Carmustine—lymphatic system cancer	0.000621	0.00172	CcSEcCtD
Ticagrelor—Dermatitis—Carmustine—lymphatic system cancer	0.00062	0.00172	CcSEcCtD
Ticagrelor—Headache—Carmustine—lymphatic system cancer	0.000617	0.00171	CcSEcCtD
Ticagrelor—Eye disorder—Methotrexate—lymphatic system cancer	0.0006	0.00166	CcSEcCtD
Ticagrelor—Vomiting—Vincristine—lymphatic system cancer	0.000598	0.00166	CcSEcCtD
Ticagrelor—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000596	0.00165	CcSEcCtD
Ticagrelor—Rash—Vincristine—lymphatic system cancer	0.000593	0.00164	CcSEcCtD
Ticagrelor—Dermatitis—Vincristine—lymphatic system cancer	0.000592	0.00164	CcSEcCtD
Ticagrelor—Headache—Vincristine—lymphatic system cancer	0.000589	0.00163	CcSEcCtD
Ticagrelor—Nausea—Carmustine—lymphatic system cancer	0.000585	0.00162	CcSEcCtD
Ticagrelor—Angiopathy—Methotrexate—lymphatic system cancer	0.000582	0.00161	CcSEcCtD
Ticagrelor—Vomiting—Mitoxantrone—lymphatic system cancer	0.000582	0.00161	CcSEcCtD
Ticagrelor—Immune system disorder—Methotrexate—lymphatic system cancer	0.00058	0.00161	CcSEcCtD
Ticagrelor—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000578	0.0016	CcSEcCtD
Ticagrelor—Rash—Mitoxantrone—lymphatic system cancer	0.000577	0.0016	CcSEcCtD
Ticagrelor—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000577	0.0016	CcSEcCtD
Ticagrelor—Headache—Mitoxantrone—lymphatic system cancer	0.000573	0.00159	CcSEcCtD
Ticagrelor—Mental disorder—Methotrexate—lymphatic system cancer	0.000562	0.00156	CcSEcCtD
Ticagrelor—Malnutrition—Methotrexate—lymphatic system cancer	0.000559	0.00155	CcSEcCtD
Ticagrelor—Nausea—Vincristine—lymphatic system cancer	0.000558	0.00155	CcSEcCtD
Ticagrelor—Nausea—Mitoxantrone—lymphatic system cancer	0.000544	0.00151	CcSEcCtD
Ticagrelor—Back pain—Methotrexate—lymphatic system cancer	0.00054	0.0015	CcSEcCtD
Ticagrelor—Vertigo—Methotrexate—lymphatic system cancer	0.000502	0.00139	CcSEcCtD
Ticagrelor—Cough—Methotrexate—lymphatic system cancer	0.000488	0.00135	CcSEcCtD
Ticagrelor—Chest pain—Methotrexate—lymphatic system cancer	0.000476	0.00132	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000472	0.00131	CcSEcCtD
Ticagrelor—Confusional state—Methotrexate—lymphatic system cancer	0.00046	0.00127	CcSEcCtD
Ticagrelor—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000447	0.00124	CcSEcCtD
Ticagrelor—Skin disorder—Methotrexate—lymphatic system cancer	0.000443	0.00123	CcSEcCtD
Ticagrelor—Hypotension—Methotrexate—lymphatic system cancer	0.000426	0.00118	CcSEcCtD
Ticagrelor—Paraesthesia—Methotrexate—lymphatic system cancer	0.000409	0.00113	CcSEcCtD
Ticagrelor—Dyspnoea—Methotrexate—lymphatic system cancer	0.000407	0.00113	CcSEcCtD
Ticagrelor—Dyspepsia—Methotrexate—lymphatic system cancer	0.000401	0.00111	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000394	0.00109	CcSEcCtD
Ticagrelor—Fatigue—Methotrexate—lymphatic system cancer	0.000393	0.00109	CcSEcCtD
Ticagrelor—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000376	0.00104	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000373	0.00103	CcSEcCtD
Ticagrelor—Abdominal pain—Methotrexate—lymphatic system cancer	0.00036	0.000999	CcSEcCtD
Ticagrelor—Body temperature increased—Methotrexate—lymphatic system cancer	0.00036	0.000999	CcSEcCtD
Ticagrelor—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000336	0.000931	CcSEcCtD
Ticagrelor—Asthenia—Methotrexate—lymphatic system cancer	0.000327	0.000907	CcSEcCtD
Ticagrelor—Pruritus—Methotrexate—lymphatic system cancer	0.000323	0.000894	CcSEcCtD
Ticagrelor—Diarrhoea—Methotrexate—lymphatic system cancer	0.000312	0.000865	CcSEcCtD
Ticagrelor—Dizziness—Methotrexate—lymphatic system cancer	0.000302	0.000836	CcSEcCtD
Ticagrelor—Vomiting—Methotrexate—lymphatic system cancer	0.00029	0.000804	CcSEcCtD
Ticagrelor—Rash—Methotrexate—lymphatic system cancer	0.000288	0.000797	CcSEcCtD
Ticagrelor—Dermatitis—Methotrexate—lymphatic system cancer	0.000287	0.000796	CcSEcCtD
Ticagrelor—Headache—Methotrexate—lymphatic system cancer	0.000286	0.000792	CcSEcCtD
Ticagrelor—Nausea—Methotrexate—lymphatic system cancer	0.000271	0.000751	CcSEcCtD
